BBT-176 is under clinical development by Bridge Biotherapeutics and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BBT-176’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BBT-176 overview
BBT-176 is under development for the treatment of non-small cell lung cancer. The drug candidate is administered through oral route. It acts by targeting epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI).
Bridge Biotherapeutics overview
Bridge Biotherapeutics is a biotechnology company that develops novel therapeutics and unmet medical needs in conditions such as ulcerative colitis, fibrotic diseases and cancers. The company product pipeline incudes BBT-401, BBT-877 and BBT-176. Its other products comprise BBT-301, BBT-301, BBT-209, BBT-207 and BBT-401. Bridge Biotherapeutics also carries out the research and development and innovation of new drugs. The company operates in the US and South Korea. Bridge Biotherapeutics is headquartered in Seongnam, South Korea.
For a complete picture of BBT-176’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
